Incremental prognostic value and underlying biological pathways of radiomics patterns in medulloblastoma

Jing Yan,Shenghai Zhang,Kay Ka-Wai Li,Weiwei Wang,Ke Li,Wenchao Duan,Binke Yuan,Li Wang,Lei Liu,Yunbo Zhan,Dongling Pei,Haibiao Zhao,Tao Sun,Chen Sun,Wenqing Wang,Zhen Liu,Xuanke Hong,Xiangxiang Wang,Yu Guo,Wencai Li,Jingliang Cheng,Xianzhi Liu,Ho-Keung Ng,Zhicheng Li,Zhenyu Zhang
DOI: https://doi.org/10.1016/j.ebiom.2020.103093
IF: 11.205
2020-11-01
EBioMedicine
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>To develop a radiomics signature for predicting overall survival (OS)/progression-free survival (PFS) in patients with medulloblastoma (MB), and to investigate the incremental prognostic value and biological pathways of the radiomics patterns.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>A radiomics signature was constructed based on magnetic resonance imaging (MRI) from a training cohort (<em>n</em> = 83), and evaluated on a testing cohort (<em>n</em> = 83). Key pathways associated with the signature were identified by RNA-seq (GSE151519). Prognostic value of pathway genes was assessed in a public GSE85218 cohort.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Findings</h3><p>The radiomics-clinicomolecular signature predicted OS (C-index 0.762) and PFS (C-index 0.697) better than either the radiomics signature (C-index: OS: 0.649; PFS: 0.593) or the clinicomolecular signature (C-index: OS: 0.725; PFS: 0.691) alone, with a better calibration and classification accuracy (net reclassification improvement: OS: 0.298, <em>P</em> = 0.022; PFS: 0.252, <em>P</em> = 0.026). Nine pathways were significantly correlated with the radiomics signature. Average expression value of pathway genes achieved significant risk stratification in GSE85218 cohort (log-rank <em>P</em> = 0.016).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Interpretation</h3><p>This study demonstrated radiomics signature, which associated with dysregulated pathways, was an independent parameter conferring incremental value over clinicomolecular factors in survival predictions for MB patients.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Funding</h3><p>A full list of funding bodies that contributed to this study can be found in the Acknowledgements section.</p>
medicine, research & experimental
What problem does this paper attempt to address?